Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Monoclonal Antibody Treatment, Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread

Mohamed A. Kamal, Andreas Kuznik, Luyuan Qi, Witold Więcek, Mohamed Hussein, Hazem E. Hassan, Kashyap Patel, Thomas Obadia, Masood Khaksar Toroghi, Daniela J. Conrado, Nidal Al-Huniti, Roman Casciano, Meagan P. O’Brien, Ruanne V. Barnabas, Myron S. Cohen, Patrick F. Smith
doi: https://doi.org/10.1101/2021.05.21.21257624
Mohamed A. Kamal
1Regeneron Pharmaceuticals; Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mohamed.kamal@regeneron.com myron_cohen@med.unc.edu patrick.smith@certara.com
Andreas Kuznik
1Regeneron Pharmaceuticals; Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luyuan Qi
2Certara; Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Witold Więcek
3Certara; London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed Hussein
1Regeneron Pharmaceuticals; Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hazem E. Hassan
1Regeneron Pharmaceuticals; Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kashyap Patel
4Certara; Princeton, New Jersey, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Obadia
2Certara; Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masood Khaksar Toroghi
1Regeneron Pharmaceuticals; Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela J. Conrado
1Regeneron Pharmaceuticals; Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nidal Al-Huniti
1Regeneron Pharmaceuticals; Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roman Casciano
4Certara; Princeton, New Jersey, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meagan P. O’Brien
1Regeneron Pharmaceuticals; Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruanne V. Barnabas
5Department of Global Health, University of Washington; Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myron S. Cohen
6Institute for Global Health and Infectious Diseases, University of North Carolina; Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mohamed.kamal@regeneron.com myron_cohen@med.unc.edu patrick.smith@certara.com
Patrick F. Smith
4Certara; Princeton, New Jersey, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mohamed.kamal@regeneron.com myron_cohen@med.unc.edu patrick.smith@certara.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background Antiviral monoclonal antibodies (mAbs) developed for treatment of COVID-19 reduce the magnitude and duration of viral shedding and can thus potentially contribute to reducing transmission of the causative virus, severe acute respiratory coronavirus 2 (SARS-CoV-2). However, use of these mAbs in combination with a vaccine program has not been considered in public health strategic planning.

Methods We developed an agent-based model to characterize SARS-CoV-2 transmission in the US population during an aggressive phase of the pandemic (October 2020 to April 2021), and simulated the effects on infections and mortality of combining mAbs as treatment and post-exposure prophylaxis (PEP) with a vaccine program plus non-pharmaceutical interventions. We also interrogated the impact of rapid diagnostic testing, increased mAb supply, and vaccine rollout.

Findings Allocation of mAbs as PEP or targeting those ≥65 years provided the greatest incremental benefits relative to vaccine in averting infections and deaths, by up to 17% and 41%, respectively. Rapid testing, facilitating earlier diagnosis and mAb use, amplified these benefits. The model was sensitive to mAb supply; doubling supply further reduced infections and mortality, by up to two-fold, relative to vaccine. mAbs continued to provide incremental benefits even as proportion of the vaccinated population increased.

Interpretation Use of anti-viral mAbs as treatment and PEP in combination with a vaccination program would substantially reduce SARS-CoV-2 transmission and pandemic burden. These results may help guide resource allocation and patient management decisions for COVID-19 and can also be used to inform public health policy for current and future pandemic preparedness.

Funding Regeneron Pharmaceuticals.

Competing Interest Statement

ICMJE disclosure forms provided by the authors are available with the full text of this article.

Funding Statement

This study was funded by Regeneron Pharmaceuticals, Inc. Writing support during manuscript development was funded by Regeneron Pharmaceuticals.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Research did not require IRB and/or ethics committee approvals.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data are available in the main text or the supplementary materials.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 25, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Monoclonal Antibody Treatment, Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Monoclonal Antibody Treatment, Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread
Mohamed A. Kamal, Andreas Kuznik, Luyuan Qi, Witold Więcek, Mohamed Hussein, Hazem E. Hassan, Kashyap Patel, Thomas Obadia, Masood Khaksar Toroghi, Daniela J. Conrado, Nidal Al-Huniti, Roman Casciano, Meagan P. O’Brien, Ruanne V. Barnabas, Myron S. Cohen, Patrick F. Smith
medRxiv 2021.05.21.21257624; doi: https://doi.org/10.1101/2021.05.21.21257624
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Monoclonal Antibody Treatment, Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread
Mohamed A. Kamal, Andreas Kuznik, Luyuan Qi, Witold Więcek, Mohamed Hussein, Hazem E. Hassan, Kashyap Patel, Thomas Obadia, Masood Khaksar Toroghi, Daniela J. Conrado, Nidal Al-Huniti, Roman Casciano, Meagan P. O’Brien, Ruanne V. Barnabas, Myron S. Cohen, Patrick F. Smith
medRxiv 2021.05.21.21257624; doi: https://doi.org/10.1101/2021.05.21.21257624

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1245)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (534)
  • Epidemiology (10032)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2467)
  • Geriatric Medicine (238)
  • Health Economics (480)
  • Health Informatics (1647)
  • Health Policy (754)
  • Health Systems and Quality Improvement (637)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11872)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2290)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1249)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (734)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4844)
  • Radiology and Imaging (843)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (652)
  • Rheumatology (286)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (269)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)